A Study Evaluating the Endovascular Treatment of Subjects With Stenotic or Restenotic Lesions of the Common Femoral Artery With the Supera Vascular Mimetic Implant Compared to Surgical Common Femoral Artery Endarterectomy

NCT04349657 · tracked via the Priya Life Science Poland tracker

Sponsor

KANDO Research

Phase

Not applicable

Started

2020-05-05

Last updated

2026-10-13

Condition(s) studied

Peripheral Arterial Disease

Investigational drug(s) / intervention(s)

Supera Peripheral Stent System treatment groupEndarterectomy treatment group

Supera Peripheral Stent System treatment group: Percutaneous endovascular stenting with the Supera Peripheral Stent System

Endarterectomy treatment group: Surgical treatment through endarterectomy

Study summary

The SUPERSURG RCT trial investigates the efficacy and safety of the endovascular treatment of stenosis or restenosis in the common femoral artery (CFA) of patients presenting with Rutherford classification 2,3 or 4 with a Supera Vascular Mimetic Implant of Abbott, compared to classic surgical common femoral artery endarterectomy. The Supera Vascular Mimetic Implant has an interwoven design and has a high crush resistance and is, when correctly implanted, an ideal stent to treat eccentric calcified plaques in the CFA.

An expected total of 143 patients will be treated with the Vascular Mimetic Implant of Abbott and compared to a control group of another 143 patients that will be treated with classic surgical endarterectomy of the common femoral artery. Assignment to the treatment groups will be at random.

Patients will be invited for a follow-up visit at 1, 6, 12, 24 and 36 months post-procedure.

The primary efficacy endpoint is defined as follows: freedom from clinically-driven target lesion revascularization and binary restenosis at 12 months. The primary safety endpoint is defined as follows: a composite of overall death, cardiac, pulmonary, renal complications, sepsis, target lesion revascularisation and wound related complications through 30 days post-index procedure.

The secondary endpoints are defined as technical success, primary patency in the deep femoral artery, primary patency in the target lesion, target lesion revascularisation, target vessel revascularisation, binary restenosis, duration of initial hospital stay, sustained clinical improvement, change of walking impairment questionnaire score from baseline, change in target limb Rutherford classification, change in target limb ABI/TBI from baseline, all cause death, thrombosis at the target lesion through 6, 12, 24 and 36 months post-procedure.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Patient is ≥18 years old * Patient presenting a score from 2 to 4 following Rutherford classification * Patient is willing to comply with specified follow-up evaluations at the specified times * Patient understands the nature of the procedure and provides written informed consent, prior to enrolment in the study * Patient has a life expectancy of at least 12 months * Prior to enrolment, the guidewire has crossed the target lesion in the endovascular arm. In the surgical arm, the endarterectomy needs to be performed with primary suture or patch implantation * De novo stenotic or restenotic (post-PTA) lesions (\<100%) located in the common femoral artery, suitable for both endovascular therapy and endarterectomy * Target lesion is located within the native CFA: localized between 1cm proximal to the origin of the circumflex iliac artery and the proximal (2cm) superficial femoral artery and deep femoral artery (2cm) (Azéma type 2 and 3 lesions) * There is angiographic evidence of a patent deep femoral artery and/or superficial femoral artery * The target lesion has angiographic evidence of \>50% stenosis. Occlusions are not allowed. Exclusion Criteria: * Presence of another stent in the target vessel that was placed during a previous procedure * Previous open surgery in the ipsilateral groin * Patients contraindicated for antiplatelet therapy, anticoagulants or thrombolytics * Patients who exhibit persistent acute intraluminal thrombus at the target lesion site * Patients with known hypersensitivity to nickel-titanium and heparin, including those patients who have had a previous incidence of heparin-induced thrombocytopenia (HIT) type II * Known allergy to contrast media that cannot be adequately pre-medicated prior to study procedure * Patients with uncorrected bleeding disorders * Female patients with child bearing potential not taking adequate contraceptives or currently breastfeeding * Ipsilateral inflow (aorto-iliac) artery treatment before target lesion treatment with a residual stenosis \>30% * Use of thrombectomy, atherectomy or laser device during procedure * Any patient considered to be hemodynamically unstable at onset of procedure * Severe medical comorbidities (untreated coronary artery disease/congestive heart failure, severe chronic obstructive pulmonary disease, metastatic malignancy, dementia, etc.) or other medical condition that would prelude compliance with the study protocol or 1-year life expectancy * Major distal amputation (above the ankle) in the study limb or non-study limb * Target lesion involves an (pseudo-)aneurysm or is adjacent to an (pseudo-)aneurysm (within 5mm) * Iliac inflow disease requiring treatment, unless the iliac artery disease is successfully treated first during the index procedure. Success is defined as ≤30% residual diameter stenosis without death or major complications * Presence of an aortic, iliac or femoral artificial graft * Occlusion in the target lesion * Presence of an interposition graft with/without profunda reimplantation

Primary outcome measure(s)

Primary efficacy endpoint at 12 months: Primary patency — 12 months post-index-procedure
To demonstrate the non-inferior efficacy in the group treated with the Supera stent compared to the group treated with endarterectomy for the treatment of atherosclerosis in the common femoral artery (CFA). Efficacy is defined as primary patency: freedom from restenosis defined as duplex ultrasound (DUS) peak systolic velocity ratio (PSVR) ≥2.4 or ≥50% stenosis as assessed by an independent DUS core lab in CFA without a previous target lesion revascularization through 12 months post-index procedure.
Primary safety endpoint at 30 days post-index procedure — 30 days post-index-procedure
To demonstrate superior safety in the group treated with the Supera stent compared to the endarterectomy group for the treatment of atherosclerosis in the CFA. Safety is defined as a composite of overall death, cardiac, pulmonary, renal complications, sepsis, target lesion revascularization (TLR) and wound-related complications (haematoma, seroma, lymphocele, lymphatic leaks with lymphatic fistula, surgical site infections (SSIs) (Szilagyi grade I, II and III)).

Trial sites (13)

Facility	City	Region
O.L.V. Hospital	Aalst	Belgium
Imelda Hospital	Bonheiden	Belgium
A.Z. Sint-Blasius	Dendermonde	Belgium
Z.O.L.	Genk	Belgium
Az Groeninge	Kortrijk	Belgium
AZ Sint-Maarten	Mechelen	Belgium
A.Z. Jan Portaels	Vilvoorde	Belgium
Maastricht UMC+	Maastricht	Limburg
Dijklander hospital	Hoorn	North Holland
St Antonius Hospital	Utrecht	Utrecht
Noordwest ziekenhuisgroep	Alkmaar	Netherlands
Bonifraterskie Centrum Medyczne	Krakow	Poland
Karol Marcinkowski Medical University	Poznan	Poland

Other trials for the same condition

Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease Recruiting

Post-Market Study of ZENFLEX Pro Stent for Femoropopliteal Artery Lesions Starting soon

Post-market Registry Study on the Safety and Efficacy of ZENFLEX Pro™ Peripheral Drug-eluting Stent System for Femoropopliteal Artery Lesions Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04349657 on ClinicalTrials.gov ↗ ← All trials in Poland